Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cord blood-derived natural killer cells (Nanfang Hospital)
- Development stage
- Unknown
- Lead developer
- Nanfang Hospital, Southern Medical University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cord blood-derived natural killer (NK) cells are an adoptive cell therapy product developed by Nanfang Hospital of Southern Medical University for the treatment of advanced hepatocellular carcinoma (HCC). These cells are isolated from umbilical cord blood and expanded ex vivo to reach therapeutic doses, typically administered at levels of at least 1×10⁹ cells per infusion. As innate immune effectors, these NK cells provide an off-the-shelf therapeutic option that can directly lyse tumor cells through the release of perforin and granzymes and the production of pro-inflammatory cytokines like interferon-gamma. In clinical studies, such as the Phase II CAN trial, these cells are being evaluated in combination with the PD-1 inhibitor camrelizumab and the VEGFR2 inhibitor apatinib to enhance anti-tumor immune responses and overcome the immunosuppressive tumor microenvironment in patients with advanced HCC.
- Other names
- NK cellCord blood derived NK cellsCB-NK cells
Beyond the preview
Go deeper on Cord blood-derived natural killer cells (Nanfang Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cord blood-derived natural killer cells (Nanfang Hospital).